Telix Pharmaceuticals to Present Advanced Prostate and Kidney Cancer Therapies at ASCO GU 2025
核心洞察
Telix Pharmaceuticals will showcase four presentations at ASCO GU 2025, including preliminary data from the CUPID (搜索) study demonstrating proof-of-concept for their alpha therapy candidate in prostate cancer (搜索).
The company's Phase 3 ProstACT GLOBAL (搜索) trial investigating TLX591 for PSMA-positive metastatic castration-resistant prostate cancer (搜索) is actively enrolling patients across multiple regions.
Two groundbreaking STARLITE trials will present updates on TLX250 combined with immunotherapy for clear cell renal cell carcinoma (搜索), positioning it as the first potential CAIX-targeting radiotherapy.
Telix Pharmaceuticals is set to present significant advances in its urologic oncology pipeline at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco, highlighting multiple therapeutic programs for prostate and kidney cancers.
Breakthrough in Prostate Cancer Treatment
For the first time in a medical congress setting, Telix will present preliminary data from the CUPID (搜索) study evaluating TLX592, their alpha therapy candidate for prostate cancer (搜索). Dr. David N. Cade, Telix Group Chief Medical Officer, emphasized the successful demonstration of clinical proof-of-concept for this innovative treatment approach.
The company's flagship Phase 3 trial, ProstACT GLOBAL (搜索), is currently enrolling patients across the United States and Asia Pacific region. This groundbreaking study evaluates TLX591, Telix's lead radio antibody-drug conjugate (rADC) therapy, in patients with PSMA-positive metastatic castration-resistant prostate cancer (搜索) who have experienced disease progression following androgen receptor pathway inhibitor treatment.
Advanced Kidney Cancer Programs
In the realm of kidney cancer treatment, Telix is advancing two significant clinical trials. The STARLITE-1 (搜索) and STARLITE-2 (搜索) studies are investigating TLX250, a novel therapeutic candidate, in combination with immunotherapy. These trials represent a pioneering approach in both treatment-naïve and late-stage patients with clear cell renal cell carcinoma (搜索) (ccRCC).
TLX250 is positioned to potentially become the first carbonic anhydrase IX (CAIX)-targeting radio antibody-drug conjugate to reach the market, with plans progressing toward a pivotal trial in ccRCC.
Comprehensive Scientific Program
The symposium will feature detailed presentations across multiple sessions, including:
- A Phase 3 study presentation by Dr. Oliver Sartor from Mayo Clinic, examining 177Lu-rosoptamab tetraxetan in combination with standard of care for metastatic castration-resistant prostate cancer
- The CUPID study results presented by Dr. David N. Cade, showcasing TLX592's potential in prostate cancer
- Updates on the STARLITE-2 trial by Dr. Darren Feldman from Memorial Sloan Kettering Cancer Center, investigating the combination of nivolumab with 177Lu-girentuximab in advanced ccRCC
- STARLITE-1 trial progress presented by Dr. Eric Jonasch from MD Anderson Cancer Center, exploring the combination of 177Lu girentuximab with cabozantinib and nivolumab in treatment-naïve ccRCC patients
These presentations underscore Telix's commitment to developing innovative radiopharmaceutical solutions for urologic cancers, potentially offering new treatment options for patients with limited therapeutic alternatives.